GlassScriptPhysician profile
Amy Jane Byer
NPI 1508915604
$958.06
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $45.17 · 2023: $178 · 2024: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $324.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $179.16 | 2019 | |
| Smith+Nephew, INC. | $78.30 | 2019 | |
| Aspira Women'S Health INC | $66.44 | 2019 | |
| Merck Sharp & Dohme LLC | $60.32 | 2019-2024 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Lilly USA, LLC | $46.32 | 2019-2020 | |
| Glaxosmithkline, LLC. | $38.07 | 2023 | Shingrix, Arexvy |
| Daiichi Sankyo INC. | $34.34 | 2019-2020 | |
| Amgen INC. | $31.44 | 2019 | |
| Amarin Pharma, INC. | $31.43 | 2019-2023 | |
| Astellas Pharma US INC | $28.57 | 2023 | Veozah |
| Tactile Systems Technology INC | $26.65 | 2019 | |
| Corcept Therapeutics | $25.89 | 2024 | Korlym |
| Teva Pharmaceuticals USA, INC. | $25.30 | 2019 | |
| Janssen Biotech, INC. | $25.18 | 2024 | Stelara |
| Allergan, INC. | $21.98 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $21.84 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.70 | 2019 | |
| Genzyme Corporation | $21.02 | 2024 | |
| Therapeuticsmd, INC. | $20.94 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.78 | 2024 | Voquezna |
| Novo Nordisk INC | $19.13 | 2023 | Wegovy, Saxenda |
| Roche Diagnostics Corporation | $18.93 | 2019 | |
| Mayne Pharma Commercial LLC | $18.05 | 2023 | |
| Alnylam Pharmaceuticals INC. | $17.78 | 2024 | Givlaari |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.94 | 2023 | Xifaxan |
| Boston Scientific Corporation | $15.97 | 2023 | Wavewriter Alpha Prime 16 |
| Janssen Pharmaceuticals, INC | $14.92 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Byer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.